Eli Lilly's Foundayo reduces sleep apnea severity by up to 44% in Phase 3 trial

• Eli Lilly's Foundayo significantly reduced sleep apnea severity in a Phase 3 trial involving adults with moderate-to-severe disease and obesity or overweight.
• Benefits occurred with or without positive airway pressure therapy; treatment also improved nighttime oxygen levels, weight and certain cardiovascular risk factors.
• Lilly plans to seek U.S. FDA approval for this sleep apnea indication by the end of 2026.
• Results were presented today at the American Heart Association Scientific Sessions 2026 and simultaneously published in JAMA.
• The safety profile was consistent with previous trials; gastrointestinal side effects were most common, generally mild to moderate.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eli Lilly and Company published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611090930PR_NEWS_USPR_____DE90498) on November 09, 2026, and is solely responsible for the information contained therein.